首页 › 基金 › Defilade Capital Management, L.P. › EVMN
Defilade Capital Management, L.P. 对 EVMN 的持仓历史
EVOMMUNE INC · 医疗保健
Defilade Capital Management, L.P. 在 Q3 2026 的 13F 申报中披露持有 EVMN(EVOMMUNE INC)1,430,573 股,市值约 US$11.8M,约占其申报组合的 1.97%,在其申报持仓中市值排名第 24 位。 Defilade Capital Management, L.P. 最近 4 个申报季度中有 4 个季度披露了 EVMN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR
Defilade Capital Management, L.P. 对 EVMN 的持仓演变
Defilade Capital Management, L.P. 于 Q4 2025 首次披露 EVMN 持仓:215,418 股(约 US$3.7M)。 该持仓在 Q1 2026 达到峰值 678,589 股,市值约 US$15.6M。 在 4 次申报中,Defilade Capital Management, L.P. 3 次增持、0 次减持、0 次保持不变。 最近一期申报(Q3 2026)显示持股 1,430,573 股、市值约 US$11.8M,环比增持 637,428 股。。 持仓曾出现大幅变动:Q1 2026 增持约 215% (随后一个季度股价下跌 42%)、Q3 2026 增持约 80% (随后一个季度股价下跌 14%)。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 215.42K | $3.69M | 新进 |
| Q1 2026 | 678.59K | $15.60M | 增持 |
| Q2 2026 | 793.14K | $10.54M | 增持 |
| Q3 2026 | 1.43M | $11.82M | 增持 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 EVMN 与 13F 数据
EVMN(EVOMMUNE INC)属于医疗保健行业。我们追踪的基金中还有 80 只申报持有 EVMN,申报仓位最大的包括:EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M), RA CAPITAL MANAGEMENT, L.P. (US$28.9M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 EVMN 的基金
- EQT Fund Management S.a r.l. 5.29M 股 · $43.68M · Q3 2026
- SymBiosis Capital Partners, LLC 1.28M 股 · $29.45M · Q1 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M 股 · $28.87M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M 股 · $15.92M · Q3 2026
- Nan Fung Group Holdings Ltd 1.44M 股 · $11.90M · Q3 2026
- Vestal Point Capital, LP 1.25M 股 · $10.32M · Q3 2026
- Kynam Capital Management, LP 1.20M 股 · $9.91M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 594.03K 股 · $4.91M · Q3 2026
- Velan Capital Investment Management LP 456.25K 股 · $3.77M · Q3 2026
- GREAT POINT PARTNERS LLC 325.00K 股 · $2.68M · Q3 2026
- NEXTBio Capital Management LP 119.06K 股 · $983.46K · Q3 2026
- Andera Partners 97.36K 股 · $804.21K · Q3 2026
更多关于 Defilade Capital Management, L.P.
常见问题
How long has Defilade Capital Management, L.P. held EVMN?
Defilade Capital Management, L.P. has disclosed EVMN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Defilade Capital Management, L.P.'s current position in EVMN?
As of Q3 2026, Defilade Capital Management, L.P. holds 1.43M shares of EVMN (EVOMMUNE INC), valued at $11.82M, representing 1.97% of its reported portfolio and ranking #24.
Has Defilade Capital Management, L.P. been buying or selling EVMN?
In the latest 13F filing (Q3 2026), Defilade Capital Management, L.P. increased its position in EVMN. The position peaked in Q1 2026 at 678.59K shares.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, RA CAPITAL MANAGEMENT, L.P., among 80 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.